U

University of Louisville | James Graham Brown Cancer Center

Research site
(Unclaimed)
Location
529 S. Jackson Street, Louisville, Kentucky, United States of America

Site insights

Top conditions

Top treatments

Pembrolizumab
Docetaxel
cisplatin
Cisplatin
Oxaliplatin
paclitaxel
Brivanib
Ipilimumab
SU5416
Irinotecan

Parent organization

This site is a part of University of Louisville

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

10 of 123 total trials

A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer) (CYCLONE 3)

The purpose of this study is to learn whether adding abemaciclib to abiraterone plus prednisone prolongs the time before prostate cancer gets worse....

Active, not recruiting
Cytochrome P-450
Antineoplastic Agents, Hormonal
Drug: Placebo for Abemaciclib
Drug: Abemaciclib

Study RGX-104-001 is a Phase 1, first-in-human, dose escalation and expansion study of RGX-104, an oral small molecule targeting the liver X receptor...

Enrolling
Endometrial Cancer
Non-small Cell Carcinoma
Drug: Docetaxel
Drug: Carboplatin

The purpose of this study is to assess the efficacy and safety of pembrolizumab plus lenvatinib plus chemotherapy compared with pembrolizumab plus ch...

Enrolling
Metastatic Esophageal Squamous Cell Carcinoma
Drug: Paclitaxel
Drug: Lenvatinib

The purpose of this study is to evaluate the long-term safety and efficacy of pembrolizumab (MK-3475) in participants from previous Merck pembrolizum...

Enrolling
Solid Tumors
Hematologic Malignancies
Drug: Pembrolizumab
Drug: Lenvatinib

This is a study to investigate the safety and efficacy of an investigational OBX-115 regimen in adult participants with advanced solid tumors.

Enrolling
Melanoma
Lung Cancer
Biological: OBX-115

Evaluate the safety and efficacy of oral azacitidne (CC-486) twice daily (BID) in subjects with myelodysplastic syndromes who failed to achieve an ob...

Active, not recruiting
Myelodysplastic Syndromes
Drug: Durvalumab
Drug: Oral Azacitidine

This Phase III clinical study will assess the impact of BMN 270 (compared to FVIII prophylaxis) on the number of bleeding episodes irrespective of ex...

Active, not recruiting
Hemophilia A
Biological: valoctocogene roxaparvovec

Prospective, interventional multicenter study evaluating adoptive cell therapy (ACT) via infusion of LN-144 (autologous TIL) followed by interleukin...

Active, not recruiting
Metastatic Melanoma
Biological: Lifileucel

Prospective, multicenter, single-arm, open label, interventional study evaluating adoptive cell therapy (ACT) with autologous tumor infiltrating lymp...

Enrolling
Cervical Carcinoma
Biological: LN-145 + pembrolizumab
Biological: LN-145

This is an open-label, multi center study to evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of PF-07248144 and early...

Enrolling
Locally Advanced or Metastatic Non-small Cell Lung Cancer
Locally Advanced or Metastatic Castration-resistant Prostate Cancer
Drug: Fulvestrant
Drug: PF-07220060

Trial sponsors

R
University of Louisville (UOFL) logo
Bristol-Myers Squibb (BMS) logo
A
Lilly logo
Novartis logo
Pfizer logo
Alliance for Clinical Trials in Oncology logo
B
C

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems